
Felipe F Casanueva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12090799/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Erectile dysfunction predicts mortality in middle-aged and older men independent of their sex steroid status. Age and Ageing, 2022, 51, .	0.7	11
2	Immunomodulatory effect of a very-low-calorie ketogenic diet compared with bariatric surgery and a low-calorie diet in patients with excessive body weight. Clinical Nutrition, 2022, 41, 1566-1577.	2.3	21
3	Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort. Andrology, 2022, 10, 1328-1338.	1.9	9
4	Weight loss normalizes enhanced expression of the oncogene survivin in visceral adipose tissue and blood leukocytes from individuals with obesity. International Journal of Obesity, 2021, 45, 206-216.	1.6	7
5	Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. ELife, 2021, 10, .	2.8	41
6	Self-Reported Shorter Than Desired Ejaculation Latency and Related Distress—Prevalence and Clinical Correlates: Results From the European Male Ageing Study. Journal of Sexual Medicine, 2021, 18, 908-919.	0.3	5
7	International Multicenter Validation Study of the SAGIT® Instrument in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3555-3568.	1.8	8
8	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, The, 2021, 398, 957-980.	6.3	1,289
9	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	5.5	315
10	Effectiveness to promote weight loss maintenance and healthy lifestyle habits of a group educational intervention program in adults with obesity: IGOBE program. Obesity Research and Clinical Practice, 2021, 15, 570-578.	0.8	2
11	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e937-e946.	1.8	207
12	National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. International Journal of Epidemiology, 2020, 49, 173-192.	0.9	44
13	An energy restrictionâ€based weight loss intervention is able to reverse the effects of obesity on the expression of liver tumorâ€promoting genes. FASEB Journal, 2020, 34, 2312-2325.	0.2	13
14	Pituitary Tumors Centers of Excellence. Endocrinology and Metabolism Clinics of North America, 2020, 49, 553-564.	1.2	34
15	Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants. Lancet, The, 2020, 396, 1511-1524.	6.3	219
16	Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study. Pituitary, 2019, 22, 476-487.	1.6	22
17	A tale of pituitary adenomas: to NET or not to NET. Pituitary, 2019, 22, 569-573.	1.6	60
18	Effect of a Very-Low-Calorie Ketogenic Diet on Circulating Myokine Levels Compared with the Effect	1.7	40

of Bariatric Surgery or a Low-Calorie Diet in Patients with Obesity. Nutrients, 2019, 11, 2368.

#	Article	IF	CITATIONS
19	Prolactin Excess and Deficiency: Epidemiology, Causes (Excluding Prolactin-Secreting Pituitary) Tj ETQq1 1 0.784	314 rgBT / 0.3	Oyerlock 10
20	Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine Connections, 2018, 7, R126-R134.	0.8	39
21	Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants. International Journal of Epidemiology, 2018, 47, 872-883i.	0.9	65
22	Elevated luteinizing hormone despite normal testosterone levels in older men—natural history, risk factors and clinical features. Clinical Endocrinology, 2018, 88, 479-490.	1.2	26
23	Effect of A Very Low-Calorie Ketogenic Diet on Food and Alcohol Cravings, Physical and Sexual Activity, Sleep Disturbances, and Quality of Life in Obese Patients. Nutrients, 2018, 10, 1348.	1.7	94
24	Symptomatic androgen deficiency develops only when both total and free testosterone decline in obese men who may have incident biochemical secondary hypogonadism: Prospective results from the EMAS. Clinical Endocrinology, 2018, 89, 459-469.	1.2	44
25	A Consensus Statement on acromegaly therapeutic outcomes. Nature Reviews Endocrinology, 2018, 14, 552-561.	4.3	382
26	Evaluation of cognitive subdomains, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D in the European Male Ageing Study. European Journal of Nutrition, 2017, 56, 2093-2103.	1.8	13
27	Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet, The, 2017, 390, 2627-2642.	6.3	5,010
28	Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary, 2017, 20, 489-498.	1.6	233
29	Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet, The, 2017, 389, 37-55.	6.3	1,667
30	Low Free Testosterone Is Associated with Hypogonadal Signs and Symptoms in Men with Normal Total Testosterone. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2647-2657.	1.8	129
31	Regulation of Growth Hormone by the Splanchnic Area. Progress in Molecular Biology and Translational Science, 2016, 138, 41-60.	0.9	1
32	The androgen receptor gene CAG repeat in relation to 4-year changes in androgen-sensitive endpoints in community-dwelling older European men. European Journal of Endocrinology, 2016, 175, 583-593.	1.9	11
33	Natural history, risk factors and clinical features of primary hypogonadism in ageing men: Longitudinal Data from the European Male Ageing Study. Clinical Endocrinology, 2016, 85, 891-901.	1.2	31
34	Obesity treatment by very low-calorie-ketogenic diet at two years: reduction in visceral fat and on the burden of disease. Endocrine, 2016, 54, 681-690.	1.1	155
35	SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study. Pituitary, 2016, 19, 39-49.	1.6	56
36	Smell–taste dysfunctions in extreme weight/eating conditions: analysis of hormonal and psychological interactions. Endocrine, 2016, 51, 256-267.	1.1	82

#	Article	IF	CITATIONS
37	CILAIR-Based Secretome Analysis of Obese Visceral and Subcutaneous Adipose Tissues Reveals Distinctive ECM Remodeling and Inflammation Mediators. Scientific Reports, 2015, 5, 12214.	1.6	48
38	Associations Between Sex Steroids and the Development of Metabolic Syndrome: A Longitudinal Study in European Men. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1396-1404.	1.8	97
39	Leptin resistance in obesity: An epigenetic landscape. Life Sciences, 2015, 140, 57-63.	2.0	178
40	Hypopituitarism After Traumatic Brain Injury. Endocrinology and Metabolism Clinics of North America, 2015, 44, 151-159.	1.2	34
41	Regulation of NUCB2/nesfatin-1 production in rat's stomach and adipose tissue is dependent on age, testosterone levels and lactating status. Molecular and Cellular Endocrinology, 2015, 411, 105-112.	1.6	21
42	Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach. Endocrine Reviews, 2015, 36, 305-342.	8.9	154
43	Development of and Recovery from Secondary Hypogonadism in Aging Men: Prospective Results from the EMAS. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3172-3182.	1.8	118
44	Obesity and the reproductive system disorders: epigenetics as a potential bridge. Human Reproduction Update, 2015, 21, 249-261.	5.2	59
45	Drug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss. Drug Design, Development and Therapy, 2014, 8, 2391.	2.0	13
46	Association of Irisin with Fat Mass, Resting Energy Expenditure, and Daily Activity in Conditions of Extreme Body Mass Index. International Journal of Endocrinology, 2014, 2014, 1-9.	0.6	151
47	Low Prolactin Is Associated with Sexual Dysfunction and Psychological or Metabolic Disturbances in Middle-Aged and Elderly Men: The European Male Aging Study (EMAS). Journal of Sexual Medicine, 2014, 11, 240-253.	0.3	63
48	Loss of Control over Eating: A Description of the Eating Disorder/Obesity Spectrum in Women. European Eating Disorders Review, 2014, 22, 25-31.	2.3	36
49	Longitudinal variation of circulating irisin after an energy restrictionâ€induced weight loss and following weight regain in obese men and women. American Journal of Human Biology, 2014, 26, 198-207.	0.8	117
50	Expert consensus document: A consensus on the medical treatment of acromegaly. Nature Reviews Endocrinology, 2014, 10, 243-248.	4.3	306
51	Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity. Endocrine, 2014, 47, 793-805.	1.1	167
52	Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metabolism: Clinical and Experimental, 2014, 63, 520-531.	1.5	111
53	Association of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone with mortality among middle-aged and older European men. Age and Ageing, 2014, 43, 528-535.	0.7	19
54	Moderate-Vigorous Physical Activity across Body Mass Index in Females: Moderating Effect of Endocannabinoids and Temperament. PLoS ONE, 2014, 9, e104534.	1.1	41

#	Article	IF	CITATIONS
55	Association of weight regain with specific methylation levels in the NPY and POMC promoters in leukocytes of obese men: A translational study. Regulatory Peptides, 2013, 186, 1-6.	1.9	96
56	Metabolic syndrome associated with hyperprolactinemia: A new indication for dopamine agonist treatment?. Endocrine, 2013, 44, 273-274.	1.1	10
57	A Five Year Prospective Investigation of Anterior Pituitary Function after Traumatic Brain Injury: Is Hypopituitarism Long-Term after Head Trauma Associated with Autoimmunity?. Journal of Neurotrauma, 2013, 30, 1426-1433.	1.7	96
58	Obesity and the future. New problems and new solutions. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2013, 60, 33-35.	0.8	4
59	Co-occurrence of non-suicidal self-injury and impulsivity in extreme weight conditions. Personality and Individual Differences, 2013, 54, 137-140.	1.6	33
60	Comparisons of Immunoassay and Mass Spectrometry Measurements of Serum Estradiol Levels and Their Influence on Clinical Association Studies in Men. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1097-E1102.	1.8	58
61	Frailty and Sexual Health in Older European Men. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2013, 68, 837-844.	1.7	32
62	Growth hormone deficiency due to sportsâ€related head trauma is associated with impaired cognitive performance in amateur boxers and kickboxers as revealed by P300 auditory eventâ€related potentials. Clinical Endocrinology, 2013, 78, 730-737.	1.2	20
63	Cohort Profile: The European Male Ageing Study. International Journal of Epidemiology, 2013, 42, 391-401.	0.9	41
64	Chrelin. , 2013, , 996-1004.		0
65	FNDC5/Irisin Is Not Only a Myokine but Also an Adipokine. PLoS ONE, 2013, 8, e60563.	1.1	478
66	Interleukin 6 Deficiency Modulates the Hypothalamic Expression of Energy Balance Regulating Peptides during Pregnancy in Mice. PLoS ONE, 2013, 8, e72339.	1.1	26
67	Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. European Journal of Endocrinology, 2012, 166, 983-991.	1.9	169
68	Association of hypogonadism with vitamin D status: the European Male Ageing Study. European Journal of Endocrinology, 2012, 166, 77-85.	1.9	166
69	Decreased ghrelin levels: the cause of obesity and weight regain?. Expert Review of Endocrinology and Metabolism, 2012, 7, 127-129.	1.2	1
70	Muscle tissue as an endocrine organ: Comparative secretome profiling of slow-oxidative and fast-glycolytic rat muscle explants and its variation with exercise. Journal of Proteomics, 2012, 75, 5414-5425.	1.2	44
71	Subclinical hypopituitarism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 461-469.	2.2	10

72 Gastric Ghrelin in the Regulation of Appetite and Metabolism. , 2012, , 73-89.

2

#	Article	IF	CITATIONS
73	Lifetime Obesity in Patients with Eating Disorders: Increasing Prevalence, Clinical and Personality Correlates. European Eating Disorders Review, 2012, 20, 250-254.	2.3	170
74	Executive Functions Profile in Extreme Eating/Weight Conditions: From Anorexia Nervosa to Obesity. PLoS ONE, 2012, 7, e43382.	1.1	180
75	Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 273-288.	1.8	1,377
76	Lower vitamin D levels are associated with depression among community-dwelling European men. Journal of Psychopharmacology, 2011, 25, 1320-1328.	2.0	99
77	Hypopituitarism following traumatic brain injury: determining factors for diagnosis. Frontiers in Endocrinology, 2011, 2, 25.	1.5	28
78	Frailty in Relation to Variations in Hormone Levels of the Hypothalamic-Pituitary-Testicular Axis in Older Men: Results From the European Male Aging Study. Journal of the American Geriatrics Society, 2011, 59, 814-821.	1.3	52
79	Elevated levels of gonadotrophins but not sex steroids are associated with musculoskeletal pain in middle-aged and older European men. Pain, 2011, 152, 1495-1501.	2.0	24
80	Secretome analysis of rat adipose tissues shows location-specific roles for each depot type. Journal of Proteomics, 2011, 74, 1068-1079.	1.2	71
81	Pituitary Stalk Dysgenesis-Induced Hypopituitarism in Adult Patients: Prevalence, Evolution of Hormone Dysfunction and Genetic Analysis. Neuroendocrinology, 2011, 93, 181-188.	1.2	39
82	Age-Related Changes in General and Sexual Health in Middle-Aged and Older Men: Results from the European Male Ageing Study (EMAS). Journal of Sexual Medicine, 2010, 7, 1362-1380.	0.3	377
83	Weight Regain after a Diet-Induced Loss Is Predicted by Higher Baseline Leptin and Lower Ghrelin Plasma Levels. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5037-5044.	1.8	132
84	Investigation of antihypothalamus and antipituitary antibodies in amateur boxers: is chronic repetitive head trauma-induced pituitary dysfunction associated with autoimmunity?. European Journal of Endocrinology, 2010, 162, 861-867.	1.9	90
85	Testing Growth Hormone Deficiency in Adults. Frontiers of Hormone Research, 2010, 38, 139-144.	1.0	18
86	Characteristics of Secondary, Primary, and Compensated Hypogonadism in Aging Men: Evidence from the European Male Ageing Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1810-1818.	1.8	481
87	Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. New England Journal of Medicine, 2010, 363, 123-135.	13.9	1,274
88	Peripheral leptin and ghrelin receptors are regulated in a tissue-specific manner in activity-based anorexia. Peptides, 2010, 31, 1912-1919.	1.2	42
89	New Guidelines for the Diagnosis of Growth Hormone Deficiency in Adults. Hormone Research in Paediatrics, 2009, 71, 112-115.	0.8	22
90	Vitamin D, parathyroid hormone and the metabolic syndrome in middle-aged and older European men. European Journal of Endocrinology, 2009, 161, 947-954.	1.9	99

#	Article	IF	CITATIONS
91	Three years prospective investigation of anterior pituitary function after traumatic brain injury: a pilot study. Clinical Endocrinology, 2008, 68, 573-579.	1.2	92
92	Assessment of Sexual Health in Aging Men in Europe: Development and Validation of the European Male Ageing Study Sexual Function Questionnaire. Journal of Sexual Medicine, 2008, 5, 1374-1385.	0.3	80
93	Hyperprolactinemia and Prolactinomas. Endocrinology and Metabolism Clinics of North America, 2008, 37, 67-99.	1.2	196
94	Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a. Proceedings of the United States of America, 2008, 105, 20452-20457.	3.3	53
95	Antipituitary antibodies after traumatic brain injury: is head trauma-induced pituitary dysfunction associated with autoimmunity?. European Journal of Endocrinology, 2008, 159, 7-13.	1.9	129
96	Combined Growth Hormone-Releasing Hormone and Growth Hormone-Releasing Peptide-6 Test for the Evaluation of Growth Hormone Secretion in Children with Growth Hormone Deficiency and Growth Hormone Neurosecretory Dysfunction. Hormone Research, 2008, 70, 215-223.	1.8	1
97	Apolipoprotein E3/E3 Genotype Decreases the Risk of Pituitary Dysfunction after Traumatic Brain Injury due to Various Causes: Preliminary Data. Journal of Neurotrauma, 2008, 25, 1071-1077.	1.7	71
98	Sensory Stimuli Directly Acting at the Central Nervous System Regulate Gastric Ghrelin Secretion. An ex Vivo Organ Culture Study. Endocrinology, 2007, 148, 3998-4006.	1.4	55
99	Pituitary functions in the acute phase of traumatic brain injury: Are they related to severity of the injury or mortality?. Brain Injury, 2007, 21, 433-439.	0.6	38
100	Kickboxing sport as a new cause of traumatic brain injury-mediated hypopituitarism. Clinical Endocrinology, 2007, 66, 360-366.	1.2	103
101	High risk of pituitary dysfunction due to aneurysmal subarachnoid haemorrhage: a prospective investigation of anterior pituitary function in the acute phase and 12 months after the event. Clinical Endocrinology, 2007, 67, 931-937.	1.2	55
102	Lysophosphatidic acid inhibits ghrelin secretion in the human gastric adenocarcinoma ACS cell lineâ€fâ~â€frole of mitogenic activated protein kinase signaling pathway. FEBS Journal, 2007, 274, 5714-5726.	2.2	4
103	One ancestor, several peptides. Molecular and Cellular Endocrinology, 2006, 256, 1-8.	1.6	63
104	Effect of obesity and morbid obesity on the growth hormone (GH) secretion elicited by the combined GHRH + GHRP-6 test. Clinical Endocrinology, 2006, 64, 667-671.	1.2	42
105	Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology, 2006, 65, 265-273.	1.2	720
106	High Risk of Hypopituitarism after Traumatic Brain Injury: A Prospective Investigation of Anterior Pituitary Function in the Acute Phase and 12 Months after Trauma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2105-2111.	1.8	285
107	Ghrelin in the Local Regulation of Endocrine Glands. , 2006, , 869-875.		0
108	Prevalence of hypopituitarism and growth hormone deficiency in adults long-term after severe traumatic brain injury. Clinical Endocrinology, 2005, 62, 525-532.	1.2	173

#	Article	IF	CITATIONS
109	Leptin and Ghrelin: What is the Impact on Pituitary Function?. Reviews in Endocrine and Metabolic Disorders, 2005, 6, 39-45.	2.6	5
110	The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men. European Journal of Endocrinology, 2005, 152, 575-580.	1.9	15
111	Low Plasma Ghrelin Level in Gastrectomized Patients Is Accompanied by Enhanced Sensitivity to the Ghrelin-Induced Growth Hormone Release. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2187-2191.	1.8	35
112	Leptin, from fat to inflammation: old questions and new insights. FEBS Letters, 2005, 579, 295-301.	1.3	337
113	Traumatic brain injury as a relevant cause of growth hormone deficiency in adults: A KIMS-based study. Archives of Physical Medicine and Rehabilitation, 2005, 86, 463-468.	0.5	42
114	Expression and Regulation of Adiponectin and Receptor in Human and Rat Placenta. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4276-4286.	1.8	203
115	Novel expression of resistin in rat testis: functional role and regulation by nutritional status and hormonal factors. Journal of Cell Science, 2004, 117, 3247-3257.	1.2	99
116	Agonist-Specific Coupling of Growth Hormone Secretagogue Receptor Type 1a to Different Intracellular Signaling Systems. Neuroendocrinology, 2004, 79, 13-25.	1.2	51
117	Desensitization and Endocytosis Mechanisms of Ghrelin-Activated Growth Hormone Secretagogue Receptor 1a. Endocrinology, 2004, 145, 930-940.	1.4	126
118	Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients. Clinical Endocrinology, 2004, 61, 250-255.	1.2	52
119	Regulation of Peptide YY Levels by Age, Hormonal, and Nutritional Status. Obesity, 2004, 12, 1944-1950.	4.0	40
120	Growth Hormone (GH) Peaks versus Areas Under the Curve in the Diagnosis of Adult GH Deficiency: Analysis of the Variables Provided by the GHRH + GHRP-6 Test. Pituitary, 2004, 7, 15-20.	1.6	6
121	Evaluation of the reproducibility of the CHRH plus GHRP-6 test of growth hormone reserve in adults. Clinical Endocrinology, 2004, 60, 185-191.	1.2	13
122	Leptin inhibits lysophosphatidic acid-induced intracellular calcium rise by a protein kinase C-dependent mechanism. Journal of Cellular Physiology, 2004, 201, 214-226.	2.0	8
123	Growth Hormone Releasing Activity of Ghrelin. , 2004, , 61-72.		Ο
124	Regulation of Ghrelin Secretion and Action. Endocrine, 2003, 22, 5-12.	2.2	51
125	Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans. Clinical Endocrinology, 2003, 58, 92-98.	1.2	21
126	Diagnosis of growth hormone deficiency after pituitary surgery: the combined acipimox/GH-releasing hormone test. Clinical Endocrinology, 2003, 58, 156-162.	1.2	2

#	Article	IF	CITATIONS
127	The effectiveness of arginineÂ+ÂGHRH test compared with GHRHÂ+ÂGHRP-6 test in diagnosing growth hormone deficiency in adults. Clinical Endocrinology, 2003, 59, 251-257.	1.2	16
128	Regulation of Resistin by Gonadal, Thyroid Hormone, and Nutritional Status. Obesity, 2003, 11, 408-414.	4.0	94
129	Resistin is expressed in different rat tissues and is regulated in a tissue- and gender-specific manner. FEBS Letters, 2003, 548, 21-27.	1.3	83
130	Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action. FEBS Letters, 2003, 552, 105-109.	1.3	129
131	Intracellular Signaling Mechanisms Mediating Chrelin-Stimulated Growth Hormone Release in Somatotropes. Endocrinology, 2003, 144, 5372-5380.	1.4	132
132	Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients. European Journal of Endocrinology, 2003, 149, 117-122.	1.9	55
133	Agouti-Related Peptide, Neuropeptide Y, and Somatostatin-Producing Neurons Are Targets for Ghrelin Actions in the Rat Hypothalamus. Endocrinology, 2003, 144, 544-551.	1.4	209
134	The Inhibition of Growth Hormone Secretion Presented in Obesity Is Not Mediated by the High Leptin Levels: A Study in Human Leptin Deficiency Patients. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 312-316.	1.8	36
135	The role of leptin in reproduction: experimental and clinical aspects. Annals of Medicine, 2002, 34, 5-18.	1.5	38
136	The Impact of Cranial Irradiation on GH Responsiveness to GHRH Plus GH-Releasing Peptide-6. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2095-2099.	1.8	24
137	Ghrelin-induced GH secretion in normal subjects is partially resistant to homologous desensitization by GH-releasing peptide-6. European Journal of Endocrinology, 2002, 147, 761-766.	1.9	10
138	Regulation of PRL release by cytokines and immunomodifiers: Interrelationships between leptin and prolactin secretion. Functional implications. NeuroImmune Biology, 2002, 2, 137-146.	0.2	0
139	Ghrelin Is No Longer Able to Stimulate Growth Hormone Secretion in Patients with Cushing's Syndrome but Instead Induces Exaggerated Corticotropin and Cortisol Responses. Neuroendocrinology, 2002, 76, 390-396.	1.2	48
140	Physical activity or food intake prior to testing did not affect the reproducibility of GH secretion elicited by GH releasing hormone plus GH-releasing hexapeptide in normal adult subjects. Clinical Endocrinology, 2002, 56, 89-94.	1.2	10
141	Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity. Clinical Endocrinology, 2002, 56, 487-492.	1.2	19
142	The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans. Clinical Endocrinology, 2002, 56, 643-648.	1.2	77
143	Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome. Clinical Endocrinology, 2002, 57, 745-749.	1.2	12
144	Effect of Food Restriction on Ghrelin in Normal ycling Female Rats and in Pregnancy. Obesity, 2002, 10, 682-687.	4.0	83

#	Article	IF	CITATIONS
145	Chrelin: the link connecting growth with metabolism and energy homeostasis. Reviews in Endocrine and Metabolic Disorders, 2002, 3, 325-338.	2.6	65
146	Evidence of Free Leptin in Human Seminal Plasma. Endocrine, 2002, 17, 169-174.	2.2	31
147	Ghrelin, A Novel Placental-Derived Hormone ¹ . Endocrinology, 2001, 142, 788-794.	1.4	336
148	Involvement of Nitric Oxide in the Regulation of Growth Hormone Secretion in Dogs. Neuroendocrinology, 2001, 74, 213-219.	1.2	19
149	Influence of cortisol status on leptin secretion. Pituitary, 2001, 4, 111-116.	1.6	76
150	Leptin, reproduction and sex steroids. Pituitary, 2001, 4, 93-99.	1.6	53
151	Growth Hormone Secretagogues as Diagnostic Tools in Disease States. Endocrine, 2001, 14, 095-099.	2.2	26
152	Developmental and Hormonal Regulation of Leptin Receptor (Ob-R) Messenger Ribonucleic Acid Expression in Rat Testis1. Biology of Reproduction, 2001, 64, 634-643.	1.2	68
153	Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue (GHS), in Humans: Comparison and Interactions with Hexarelin, a Nonnatural Peptidyl GHS, and GH-Releasing Hormone1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1169-1174.	1.8	428
154	Criteria for Cure of Acromegaly: A Consensus Statement ¹ â€. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 526-529.	1.8	779
155	Gestational Profile of Leptin Messenger Ribonucleic Acid (mRNA) Content in the Placenta and Adipose Tissue in the Rat, and Regulation of the mRNA Levels of the Leptin Receptor Subtypes in the Hypothalamus During Pregnancy and Lactation1. Biology of Reproduction, 2000, 62, 698-703.	1.2	122
156	Leptin Regulation of Prepro-orexin and Orexin Receptor mRNA Levels in the Hypothalamus. Biochemical and Biophysical Research Communications, 2000, 269, 41-45.	1.0	179
157	Regulation of in vivo TSH secretion by leptin. Regulatory Peptides, 2000, 92, 25-29.	1.9	98
158	GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet, The, 2000, 356, 1137-1142.	6.3	177
159	Elevated serum leptin concentrations induced by experimental acute inflammation. Life Sciences, 2000, 67, 2433-2441.	2.0	116
160	Prolactin Stimulates Leptin Secretion by Rat White Adipose Tissue1. Endocrinology, 1999, 140, 5149-5153.	1.4	86
161	Serum leptin levels in women throughout pregnancy and the postpartum period and in women suffering spontaneous abortion. Clinical Endocrinology, 1999, 50, 211-216.	1.2	86
162	Neuroendocrine Regulation and Actions of Leptin. Frontiers in Neuroendocrinology, 1999, 20, 317-363.	2.5	345

#	Article	IF	CITATIONS
163	Growth Hormone Secretagogues: Physiological Role and Clinical Utility. Trends in Endocrinology and Metabolism, 1999, 10, 30-38.	3.1	141
164	Growth Hormone Secretagogues. Physiological Role and Clinical Implications. , 1999, , 209-224.		2
165	7 Interaction between body composition, leptin and growth hormone status. Bailliere's Clinical Endocrinology and Metabolism, 1998, 12, 297-314.	1.0	45
166	Serum Leptin Levels in Male Marathon Athletes before and after the Marathon Run1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2376-2379.	1.8	88
167	Preserved Growth Hormone (GH) Secretion in Aged and Very Old Subjects after Testing with the Combined Stimulus GH-Releasing Hormone plus GH-Releasing Hexapeptide-6 ¹ . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2569-2572.	1.8	37
168	Gender Differences in Both Spontaneous and Stimulated Leptin Secretion by Human Omental Adipose Tissue in Vitro: Dexamethasone and Estradiol Stimulate Leptin Release in Women, But Not in Men1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2149-2155.	1.8	198
169	Interaction between Leptin and Neuropeptide Y on in vivo Growth Hormone Secretion. Neuroendocrinology, 1998, 68, 187-191.	1.2	41
170	Influence of Endogenous Leptin Tone on the Estrous Cycle and Luteinizing Hormone Pulsatility in Female Rats. Neuroendocrinology, 1997, 66, 375-377.	1.2	142
171	Serum Leptin Levels in Normal Children: Relationship to Age, Gender, Body Mass Index, Pituitary-Gonadal Hormones, and Pubertal Stage ¹ . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2849-2855.	1.8	390
172	Synthesis of Leptin in Human Placenta. Endocrinology, 1997, 138, 4501-4504.	1.4	305
173	Serum Immunoreactive Leptin Concentrations in Patients with Anorexia Nervosa before and after Partial Weight Recovery. Biochemical and Molecular Medicine, 1997, 60, 116-120.	1.5	65
174	Serum leptin concentrations in patients with anorexia nervosa, bulimia nervosa and non-specific eating disorders correlate with the body mass index but are independent of the respective disease. Clinical Endocrinology, 1997, 46, 289-293.	1.2	103
175	The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary CH reserve in man. Clinical Endocrinology, 1996, 45, 543-551.	1.2	11
176	Diagnosis of growth hormone deficiency in adulthood. European Journal of Endocrinology, 1996, 135, 168-170.	1.9	17
177	Growth Hormone Secretagogues in Disease States Associated with Altered Growth Hormone Secretion. , 1996, , 389-401.		1
178	Influence of metabolic substrates and obesity on growth hormone secretion. Trends in Endocrinology and Metabolism, 1995, 6, 55-59.	3.1	100
179	Oral dexamethasone administration: new pharmacological test for the assessment of growth hormone secretion. European Journal of Endocrinology, 1994, 131, 598-601.	1.9	6
180	Inhibition of growth hormone release after the combined administration of CHRH and GHRPâ€6 in patients with Cushing's syndrome. Clinical Endocrinology, 1994, 41, 649-654.	1.2	59

#	Article	IF	CITATIONS
181	Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome. Clinical Endocrinology, 1993, 38, 399-403.	1.2	27
182	Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. Clinical Endocrinology, 1993, 39, 337-343.	1.2	21
183	Modulation by Glucocorticoids of Growth Hormone Secretion in Patients with Different Pituitary Tumors. Neuroendocrinology, 1993, 58, 465-472.	1.2	11
184	Regulation of His-dTrp-Ala-Trp-dPhe-Lys-NH2 (GHRP-6)-Induced GH Secretion in the Rat. Neuroendocrinology, 1993, 57, 247-256.	1.2	64
185	Physiology of Growth Hormone Secretion and Action. Endocrinology and Metabolism Clinics of North America, 1992, 21, 483-517.	1.2	148
186	Corticosteroid-induced growth hormone secretion in normal and obese subjects. Clinical Endocrinology, 1991, 35, 485-490.	1.2	28
187	ROLE OF CHOLINERGIC MUSCARINIC PATHWAYS ON THE FREE FATTY ACID INHIBITION OF GH RESPONSES TO GHRH IN NORMAL MEN. Clinical Endocrinology, 1990, 33, 171-176.	1.2	17
188	Acute Administration of Corticoids: A New and Peculiar Stimulus of Growth Hormone Secretion in Man*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 234-237.	1.8	136
189	Activation of Cholinergic Neurotransmission by Pyridostigmine Reverses the Inhibitory Effect of Hyperglycemia on Growth Hormone (GH) Releasing Hormone-Induced GH Secretion in Man: Does Acute Hyperglycemia Act through Hypothalamic Release of Somatostatin?. Neuroendocrinology, 1989, 49, 551-554	1.2	67
190	Cholinergic Receptor Activation by Pyridostigmine Restores Growth Hormone (GH) Responsiveness to GH Releasing Hormone Administration in Obese Subjects: Evidence for Hypothalamic Somatostatinergic Participation in the Blunted GH Release of Obesity*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 290-293.	1.8	115
191	Steroids and neuroendocrine function in anorexia nervosa. The Journal of Steroid Biochemistry, 1987, 27, 635-640.	1.3	14